IP Verse

Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention

Patent No. EP3846810 (titled "Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention") was filed by ELI Lilly on Sep 3, 2019. The application was issued on Oct 18, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSJul 15, 2024VON KAUFFMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3846810

ELI LILLY
Application Number
EP19773583A
Filing Date
Sep 3, 2019
Status
Granted And Under Opposition
Sep 15, 2023
Publication Date
Oct 18, 2023
External Links
Slate, Register , Google Patents